(AOF) – Noxxon announced on Wednesday evening the extension of the agreement with Atlas Special Opportunities (ASO) relating to the additional provision of up to 17 million euros in equity-related securities and the issuance of 2,419 convertible bonds (including 44 convertible bonds issued in connection with transaction costs) for a total nominal value of 2.419 million euros.
“This capital increase further strengthens Noxxon’s financial visibility and allows us to focus on achieving our key operational objectives, including the finalization of the phase 1/2 GLORIA study on NOX-A12 underway in cancer. of the brain, the advancement of the GLORIA expansion arms evaluating other associations and the launch of two new studies: a major phase 2/3 study in glioblastoma and a phase 2 study in pancreatic cancer “, a explained Bryan Jennings, CFO of Noxxon.
“In addition, the extension of this financing allows sufficient financing capacity to continue our operations for most of the year 2022, in accordance with the current business plan,” he added.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.